PTGS2 and neoplasm: Crucially, however, triple therapy combining CTX, ICB and COX-2 inhibition uniquely impaired tumor progression, with approximately 30% of mice exhibiting tumor shrinkage two weeks following treatment (Fig. 6b, c).